Summary & Overview
HCPCS Q0177: Hydroxyzine Pamoate 25 mg Oral Anti‑emetic
HCPCS Level II code Q0177 denotes hydroxyzine pamoate 25 mg oral as an FDA‑approved anti‑emetic intended to serve as a complete therapeutic substitute for an IV anti‑emetic during chemotherapy, with use limited to a 48‑hour regimen. Nationwide, this code matters for oncology practices, infusion centers, and payers because it formalizes billing for an oral alternative to IV anti‑emetics used at the point of chemotherapy care. Adoption of Q0177 affects medication administration workflows, prior authorization pathways, and outpatient infusion billing.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, and the implications for billing and coverage determinations. The publication outlines what to expect in payer coverage patterns, common modifier usage, and where to look for policy updates that may affect authorization and payment for oral anti‑emetic substitution during chemotherapy. The summary also highlights benchmarks and practical considerations for documentation and coding consistency across oncology settings. Data not available in the input for specific payers’ policy details or utilization benchmarks.
Billing Code Overview
HCPCS Level II code Q0177 describes hydroxyzine pamoate, 25 mg, oral, FDA‑approved prescription anti‑emetic, intended for use as a complete therapeutic substitute for an IV anti‑emetic at the time of chemotherapy treatment, with a dosing limit of not to exceed a 48 hour dosage regimen.
Service Type: Oral anti‑emetic medication administered to manage chemotherapy‑related nausea and vomiting as a substitute for IV anti‑emetics.
Typical Site of Service: Oncology outpatient infusion centers, clinics, or other chemotherapy treatment settings where patients receive anti‑emetic therapy concurrent with IV chemotherapy.
Data not available in the input for Associated Taxonomies, ICD‑10 Diagnoses, Related Codes, and Service Line.
Clinical & Coding Specifications
Clinical Context
A 58-year-old female with metastatic breast cancer presents to the outpatient oncology infusion suite for her scheduled chemotherapy infusion. The patient has a history of severe chemotherapy-induced nausea with prior IV anti-emetics and requests an oral alternative that can be administered at the time of infusion. The oncologist prescribes hydroxyzine pamoate 25 mg orally as an FDA‑approved anti‑emetic substitute to provide short-term control of acute nausea during and immediately after chemotherapy, not to exceed a 48‑hour regimen.
The clinical workflow: the oncology nurse verifies the prescription and documents indication in the electronic medical record, screens for allergies and QT prolongation risk, administers the single oral dose in the infusion area prior to chemotherapy start, and provides instructions for up to 48 hours of use. Nursing documents medication administration time, lot number, and any adverse reactions. Billing uses HCPCS Level II code Q0177 to report provision of hydroxyzine pamoate 25 mg as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment. Common payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for prior authorization, coverage, and claims adjudication processes.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / default |